Floatz logo

dt2216

Recurrent Childhood Malignant Solid Neoplasm

Children's Oncology GroupSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Recurrent Childhood Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 1/2CCC

Same molecule, other indications

dt2216 is also rated in:

fibrolamellar hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Refractory Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
Recurrent Malignant Solid NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →